[1] Friedrich MJ. Depression is the leading cause of disability around the world [J]. JAMA, 2017, 317(15): 1517. [2] Smith K. Mental health: a world of depression [J]. Nature, 2014, 515(7526): 181. [3] Hill AS, Sahay A, Hen R. Increasing adult hippocampal neurogenesis is sufficient to reduce anxiety and depression-like behaviors [J]. Neuropsychopharmacology, 2015, 40(10): 2368-2378. [4] Toni N, Teng EM, Bushong EA, et al. Synapse formation on neurons born in the adult hippocampus [J]. Nat Neurosci, 2007, 10(6): 727-734. [5] 石旺清, 郑关毅, 陈晓东, 等. 大鼠脑缺血/再灌注后bFGF和GAP-43的表达与神经再生 [J]. 中国应用生理学杂志, 2013, 29(1): 63-67. [6] Papakostas GI, Johe K, Hand H, et al. A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder [J]. Mol Psychiatry, 2019. doi: 10.1038/s41380-018-0334-8. [7] Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants [J]. Science, 2003, 301(5634): 805-809. [8] Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression [J]. Mol Psychiatry, 2006, 11(5): 514-522. [9] Bessa J M, Ferreira D, Melo I, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling [J]. Mol Psychiatry, 2009, 14(8): 764-773. [10]Kin K, Yasuhara T, Kameda M, et al. Hippocampal neurogenesis of Wistar Kyoto rats is congenitally impaired and correlated with stress resistance [J]. Behav Brain Res, 2017, 329: 148-156. [11]Nagasawa M, Otsuka T, Yasuo S, et al. Chronic imipramine treatment differentially alters the brain and plasma amino acid metabolism in Wistar and Wistar Kyoto rats [J]. Eur J Pharmacol, 2015, 762: 127-135. [12]Nam H, Clinton SM, Jackson NL, et al. Learned helplessness and social avoidance in the Wistar-Kyoto rat [J]. Front Behav Neurosci, 2014, 8: 109. [13]Jiang H, Zhang X, Wang Y, et al. Mechanisms underlying the antidepressant response of acupuncture via PKA/CREB signaling pathway [J]. Neural Plast, 2017, 2017: 4135164. [14]Schulz D. Acute food deprivation separates motor-activating from anxiolytic effects of caffeine in a rat open field test model [J]. Behav Pharmacol, 2018, 29(6): 543-546. [15]Overstreet DH, Friedman E, Mathe AA, et al. The flinders sensitive line rat: a selectively bred putative animal model of depression [J]. Neurosci Biobehav Rev, 2005, 29(4-5): 739-759. [16]Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report [J]. Am J Psychiatry, 2006, 163(11): 1905-1917. [17]Malhi GS, Mann JJ. Depression [J]. The Lancet, 2018, 392(10161): 2299-2312. [18]Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis [J]. Neuropsychopharmacology, 2013, 38(12): 2467-2474. [19]Chadwick W, Mitchell N, Caroll J, et al. Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity [J]. PLoS One, 2011, 6(6): e21660. [20]Gulbins E, Palmada M, Reichel M, et al. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs [J]. Nature Medicine, 2013, 19(7): 934-938. [21]Grassme H, Jernigan PL, Hoehn RS, et al. Inhibition of acid sphingomyelinase by antidepressants counteracts stress-induced activation of P38-kinase in major depression [J]. Neurosignals, 2015, 23(1): 84-92. [22]Duman RS, Malberg J, Nakagawa S, et al. Neuronal plasticity and survival in mood disorders [J]. Biol Psychiatry, 2000, 48(8): 732-739. [23]Galecki P, Talarowska M, Anderson G, et al. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression [J]. Med Sci Monit, 2015, 21: 1535-1547. [24]Anderson G, Maes M. Reconceptualizing adult neurogenesis: role for sphingosine-1-phosphate and fibroblast growth factor-1 in co-ordinating astrocyte-neuronal precursor interactions [J]. CNS Neurol Disord Drug Targets, 2014, 13(1): 126-136. [25]Fava M, Johe K, Ereshefsky L, et al. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients [J]. Mol Psychiatry, 2016, 21(10): 1372-1380. |